ஒருங்கிணைந்த மருந்து கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஒருங்கிணைந்த மருந்து கண்டுபிடிப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஒருங்கிணைந்த மருந்து கண்டுபிடிப்பு Today - Breaking & Trending Today

Oncology and Immuno-Oncology Precision Medicines: From Hit-Finding to Pre-Clinical Candidate Selection, Upcoming Webinar Hosted by Xtalks


Oncology and Immuno-Oncology Precision Medicines: From Hit-Finding to Pre-Clinical Candidate Selection, Upcoming Webinar Hosted by Xtalks
Share Article
In this free webinar, the featured speakers will shed light on the DRIVE-SM (DRug Integrative discoVEry for Small Molecule) offering, from hit-finding to preclinical models, to assess drug pharmacology in oncology. The presenters will discuss the input of DNA encoding libraries (DEL), development of biostructural techniques and translation of pharmacological tools from in vitro to in vivo. They will also present study cases related to the characterization of specific N-α-Acetyltransferase 50 (Naa50) inhibitors identified using a DNA-encoded library, as well as use of patient-derived xenograft (PDX) cancer models. ....

United Kingdom , Barrya Morgan , Honeycomb Worldwide Inc , Drug Discovery Services , Head Of In Vivo Sciences , Business Unit Service At Oncodesign , Small Molecule , Integrated Drug Discovery , Patient Derived Xenograft , Drug Positioning , Breast Cancer , Chief Scientist Officer , Olivier Duchamp , Vivo Sciences , Business Unit Service , Immuno Oncology Precision Medicines , From Hit Finding , Pre Clinical Candidate , Life Science , ஒன்றுபட்டது கிஂக்டம் , தேன்கூடு உலகளவில் இன்க் , மருந்து கண்டுபிடிப்பு சேவைகள் , சிறிய மூலக்கூறு , ஒருங்கிணைந்த மருந்து கண்டுபிடிப்பு , மருந்து பொஸிஶநிஂக் , மார்பக புற்றுநோய் ,

Wren Therapeutics Announces Financing of 12.4 Million (c. $17.0 Million)


Posted on
7440
Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing.
This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures.
Dr. Samuel Cohen, Chief Executive Officer of Wren, commented: “This support from both our existing as well as our new shareholders will accelerate the advancement of our two lead small molecule programs towards the clinic for the potential treatment of Alzheimer’s disease and various synucleinopathies including Parkinson’s disease.” ....

United States , Rowen Hughes , Samuel Cohen , Emer Reynolds , Lund University Sweden , Milken Institute , National Cancer Institute , Dartmouth College , Board Of Bausch Health , Baupost Group , Board Of Directors At Radius Health , Fidelity Investments Company , Celularity Inc , University Of Cambridge United Kingdom , Georgetown University , Radius Health , Clinical Development , Bausch Health , University Of Texas Md Anderson Cancer Center , National Institutes Of Health , Drug Administration , Bipartisan Policy Center , Samaritan Health Initiatives Inc , Eisai Co Ltd , Head Of Corporate Development At Intarcia Therapeutics , Wren Therapeutics Ltd ,